In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $169.05 in the prior trading day, Repligen Corp (NASDAQ: RGEN) closed at $166.42, down -1.56%. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 0.66 million shares were traded. RGEN stock price reached its highest trading level at $168.66 during the session, while it also had its lowest trading level at $164.23.
Ratios:
Our goal is to gain a better understanding of RGEN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.98. For the most recent quarter (mrq), Quick Ratio is recorded 7.14 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In the most recent recommendation for this company, HSBC Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $150.
On September 22, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $155.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 17 ’25 when DAWES KAREN A sold 275 shares for $161.00 per share. The transaction valued at 44,275 led to the insider holds 91,821 shares of the business.
DAWES KAREN A bought 275 shares of RGEN for $44,275 on Dec 17 ’25. On Nov 25 ’25, another insider, Loeillot Olivier, who serves as the Chief Executive Officer of the company, sold 7,041 shares for $170.00 each. As a result, the insider received 1,196,970 and left with 35,898 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 9367906304 and an Enterprise Value of 9308026880. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6475.49, and their Forward P/E ratio for the next fiscal year is 80.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.23 while its Price-to-Book (P/B) ratio in mrq is 4.50. Its current Enterprise Value per Revenue stands at 13.149 whereas that against EBITDA is 67.832.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.14, which has changed by 0.091631174 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 4.41%, while the 200-Day Moving Average is calculated to be 22.33%.
Shares Statistics:
The stock has traded on average 822.24K shares per day over the past 3-months and 499490 shares per day over the last 10 days, according to various share statistics. A total of 56.28M shares are outstanding, with a floating share count of 53.22M. Insiders hold about 5.45% of the company’s shares, while institutions hold 107.15% stake in the company. Shares short for RGEN as of 1765756800 were 4120083 with a Short Ratio of 5.01, compared to 1763078400 on 4085106. Therefore, it implies a Short% of Shares Outstanding of 4120083 and a Short% of Float of 9.87.
Earnings Estimates
Investors are keenly observing as 18.0 analysts analyze and rate . The current performance of Repligen Corp (RGEN) in the stock market.The consensus estimate for the next quarter is $0.45, with high estimates of $0.51 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.7 and $1.64 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.08, with 19.0 analysts recommending between $2.47 and $1.76.
Revenue Estimates
18 analysts predict $193.02M in revenue. The current quarter. It ranges from a high estimate of $196M to a low estimate of $189M. As of . The current estimate, Repligen Corp’s year-ago sales were $167.55MFor the next quarter, 18 analysts are estimating revenue of $191.98M. There is a high estimate of $197M for the next quarter, whereas the lowest estimate is $186.9M.
A total of 20 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $737M, while the lowest revenue estimate was $729.3M, resulting in an average revenue estimate of $733.13M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $823.87M in the next fiscal year. The high estimate is $834.56M and the low estimate is $794.14M.
